このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Viracta Therapeutics マネジメント

マネジメント基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Mark Rothera

最高経営責任者

US$1.5m

報酬総額

CEO給与比率	40.5%
CEO在任期間	2yrs
CEOの所有権	n/a
経営陣の平均在職期間	3.2yrs
取締役会の平均在任期間	3.6yrs

経営陣の近況

Recent updates

Viracta Therapeutics names Mark Rothera as new CEO

Sep 19

Viracta Therapeutics gets European orphan drug designation for lymphoma combo treatment

Sep 07

Viracta Therapeutics GAAP EPS of -$0.28

Aug 09

Viracta Therapeutics files for $200M mixed shelf offering

May 28

CEO報酬分析

Viracta Therapeutics の収益と比較して、Mark Rothera の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$45m
Mar 31 2024	n/a	n/a	-US$48m
Dec 31 2023	US$1m	US$590k	-US$51m
Sep 30 2023	n/a	n/a	-US$48m
Jun 30 2023	n/a	n/a	-US$53m
Mar 31 2023	n/a	n/a	-US$51m
Dec 31 2022	US$6m	US$167k	-US$49m

報酬と市場: Markの総報酬 ($USD 1.46M ) は、 US市場 ($USD 680.04K ) の同規模の企業の平均を上回っています。

報酬と収益: Markの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Mark Rothera (61 yo)

2yrs

在職期間

US$1,456,596

報酬

Mr. Mark Andrew Rothera serves as Chief Executive Officer, President & Director of Viracta Therapeutics, Inc. since September 19, 2022. He served as President, Chief Executive Officer and Executive Directo...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Mark Rothera	CEO, President & Director	2yrs	US$1.46m	データなし
Darrel Cohen	Chief Medical Officer	1.1yrs	US$1.05m	0% $ 0
Susan Perrine	Scientific Founder and Consultant	13.8yrs	データなし	データなし
Ronald Berenson	Co-Founder and Consultant	13.8yrs	データなし	データなし
George Hillman	Co-Founder	no data	データなし	データなし
Thalia Papayannopoulou	Co-Founder	no data	データなし	データなし
Robert Williams	Co-Founder	no data	データなし	データなし
Douglas Faller	Scientific Founder & Chairman of Scientific Advisory Board	no data	データなし	データなし
Michael Faerm	Chief Financial Officer	less than a year	データなし	データなし
Ayman El-Guindy	Chief Scientific Officer	3.2yrs	データなし	データなし
Cheryl Madsen	Senior Vice President of Regulatory Affairs	3.5yrs	データなし	データなし
Patric Nelson	Senior Vice President of Business Development & Corporate Strategy	3.2yrs	データなし	データなし

3.2yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: VIRXの経営陣は経験豊富であると考えられます ( 2.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Mark Rothera	CEO, President & Director	2yrs	US$1.46m	データなし
Douglas Faller	Scientific Founder & Chairman of Scientific Advisory Board	no data	データなし	データなし
Ivor Royston	Director	3.6yrs	US$90.76k	2.11% $ 188.3k
Thomas Darcy	Independent Director	3.6yrs	US$113.26k	0% $ 0
Ronald Levy	Member of Scientific Advisory Board	6yrs	データなし	データなし
Carl June	Member of Scientific Advisory Board	6yrs	データなし	データなし
Barry Simon	Independent Director	3.5yrs	US$110.76k	0% $ 0
Roger Pomerantz	Independent Chairman of the Board	3.6yrs	US$210.27k	0.30% $ 26.5k
Lawrence Young	Member of Scientific Advisory Board	6yrs	データなし	データなし
Robert Baiocchi	Member of Scientific Advisory Board	6yrs	データなし	データなし
Pierluigi Porcu	Member of Scientific Advisory Board	6yrs	データなし	データなし
Stephen Rubino	Independent Director	3.5yrs	US$108.26k	0% $ 0

3.6yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: VIRXの取締役会は経験豊富であると考えられます ( 3.5年の平均在任期間)。

Viracta Therapeutics マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

High number of new directors

High number of new directors

Recent updates

New major risk - Market cap size

New major risk - Financial position

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

New major risk - Revenue and earnings growth

Viracta Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing under Nasdaq Listing Rule 5450(a)(1)

Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

New major risk - Revenue and earnings growth

Price target decreased by 20% to US$7.00

Viracta Therapeutics, Inc. Provides Clinical Update

Viracta Therapeutics Announces Interim Data from Phase 1B/2 Clinical Trial of Nana-Val in Patients with Epstein-Barr Virus-Positive Solid Tumors That Show Confirms Tumor Responses At Higher Dose Levels

Viracta Therapeutics, Inc. Receives A Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC

Viracta Therapeutics, Inc. Receives A Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

Price target decreased by 36% to US$9.40

Price target decreased by 9.1% to US$14.00

Viracta Therapeutics’ Pivotal Naval-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

Viracta Therapeutics, Inc. Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives

Viracta Therapeutics, Inc. Announces Preliminary Dose-Ranging Data from the Phase 1B/2 Trial of Nana-Val in Patients

Price target decreased to US$15.00

High number of new directors

High number of new directors

High number of new directors

Viracta Therapeutics, Inc. Announces CEO Changes

Viracta Therapeutics names Mark Rothera as new CEO

Viracta Therapeutics gets European orphan drug designation for lymphoma combo treatment

CEO, President & Director exercised options and sold US$54k worth of stock

Viracta Therapeutics, Inc. Announces Resignation of Michael Huang as Director

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

Viracta Therapeutics GAAP EPS of -$0.28

Viracta Therapeutics, Inc.(NasdaqGS:VIRX) dropped from Russell 2500 Value Index

Viracta Therapeutics, Inc. Provides an Update on the Phase 1b/2 Trial of Nana-Val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Price target decreased to US$21.40

Less than half of directors are independent

Viracta Therapeutics, Inc. Announces That Gur Roshwalb Will Not Stand for Re-Election At the Company’s 2022 Annual Meeting of Stockholders

Price target increased to US$31.50

Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors

Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021

CEO, President & Director exercised options and sold US$133k worth of stock

Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Viracta Therapeutics, Inc. Announces the Initiation of Naval-1, A Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma

Viracta Therapeutics files for $200M mixed shelf offering

Viracta Therapeutics, Inc. Announces Executive Changes

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34